AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26652589 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Care for People with Cancer (DCPC)
Number of subjects: 0
Study 26652589 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24723075 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA)
Number of subjects: 2715
Study 24723075 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose statin (LDS)
Number of subjects: 2715
Study 24723075 — intervention group
Group type: EXPERIMENTAL
Intervention: FA + Low-dose statin (LDS)
Number of subjects: 2715
Study 24723075 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose statin (MDS)
Number of subjects: 2715
Study 24723075 — intervention group
Group type: EXPERIMENTAL
Intervention: FA + Moderate-dose statin (MDS)
Number of subjects: 2715
Study 24723075 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statin (HDS)
Number of subjects: 2715
Study 21562420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg intrathecal hydromorphone
Number of subjects: 60
Study 21562420 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg intrathecal hydromorphone
Number of subjects: 60
Study 21562420 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 μg intrathecal hydromorphone
Number of subjects: 60
Study 21562420 — intervention group
Group type: COMPARATOR
Intervention: 0.0 μg intrathecal hydromorphone (control group)
Number of subjects: 60
Study 19708636 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement (Group A1)
Number of subjects: 20
Study 19708636 — intervention group
Group type: EXPERIMENTAL
Intervention: Reattachment (Group A2)
Number of subjects: 20
Study 19708636 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (overall)
Number of subjects: 20
Study 17417700 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 or 5 mg)
Number of subjects: 17
Study 17417700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16393308 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day RLT (rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., tinidazole 500 mg b.d. for 7 days)
Number of subjects: 85
Study 16393308 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day RLT (rabeprazole 20 mg b.d., levofloxacin 500 mg b.d., tinidazole 500 mg b.d. for 4 days)
Number of subjects: 85
Study 15372129 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 33
Study 15372129 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 33
Study 15372129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11138570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g x kg(‐1) sodium citrate
Number of subjects: 8
Study 11138570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g x kg(‐1) sodium citrate
Number of subjects: 8
Study 11138570 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g x kg(‐1) sodium citrate
Number of subjects: 8
Study 11138570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium carbonate, 0.1 g x kg(‐1))
Number of subjects: 8
Study 8780802 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rt-PA (recombinant tissue plasminogen activator)
Number of subjects: 0
Study 8780802 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1353679 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 52
Study 1353679 — intervention group
Group type: COMPARATOR
Intervention: No Doxapram (Control)
Number of subjects: 52
Study 6233481 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy (+) group
Number of subjects: 2
Study 6233481 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy (−) group
Number of subjects: 2
Study 6233481 — intervention group
Group type: EXPERIMENTAL
Intervention: Concanavalin‐A induced suppressor cells (ConAS) in peripheral blood lymphocytes (PBL)
Number of subjects: 2
Study 6233481 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous suppressor cells (SpS) in peripheral blood lymphocytes (PBL)
Number of subjects: 2
Study 6233481 — intervention group
Group type: EXPERIMENTAL
Intervention: ConAS activities in spleen cells (SC)
Number of subjects: 2
Study 6233481 — intervention group
Group type: EXPERIMENTAL
Intervention: SpS activities in splenic vein lymphocytes (SVL)
Number of subjects: 2
Study 30958844 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dental pain
Number of subjects: 1589
Study 30958844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic, clinical and behavioral/psychosocial indicators
Number of subjects: 1589
Study 29095681 — intervention group
Group type: EXPERIMENTAL
Intervention: ConquerFear intervention (five face-to-face sessions)
Number of subjects: 222
Study 29095681 — intervention group
Group type: EXPERIMENTAL
Intervention: ConquerFear intervention
Number of subjects: 222
Study 29095681 — intervention group
Group type: COMPARATOR
Intervention: Attention control (Taking-it-Easy relaxation therapy)
Number of subjects: 222
Study 26825000 — intervention group
Group type: COMPARATOR
Intervention: 23vPPV
Number of subjects: 194
Study 26825000 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 194
Study 26825000 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 194
Study 25011490 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of VaD patients
Number of subjects: 0
Study 21970862 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing sessions delivered by a school nurse
Number of subjects: 37
Study 19947265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined electroacupuncture and Chinese herb group
Number of subjects: 126
Study 19947265 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture group
Number of subjects: 126
Study 19947265 — intervention group
Group type: COMPARATOR
Intervention: Chinese herb group
Number of subjects: 126
Study 17368412 — intervention group
Group type: EXPERIMENTAL
Intervention: RITE intervention
Number of subjects: 186
Study 17368412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study 15111526 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare (glucometer transmission with feedback)
Number of subjects: 31
Study 15111526 — intervention group
Group type: COMPARATOR
Intervention: Control (glucometer transmission without feedback)
Number of subjects: 31
Study 15111526 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of telecare trials
Number of subjects: 31
Study 11525706 — intervention group
Group type: EXPERIMENTAL
Intervention: Crotalinae polyvalent immune Fab (Fab AV) - PRN group (as-needed)
Number of subjects: 31
Study 11525706 — intervention group
Group type: EXPERIMENTAL
Intervention: Crotalinae polyvalent immune Fab (Fab AV) - Scheduled group (initial dose plus repeated treatments)
Number of subjects: 31
Study 11525706 — intervention group
Group type: EXPERIMENTAL
Intervention: Crotalinae polyvalent immune Fab (Fab AV) - Follow-up
Number of subjects: 31
Study 9589688 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg daily for 2 weeks)
Number of subjects: 75
Study 9589688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8053577 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia without leg-warming (leg-skin temperature approximately 34 degrees C)
Number of subjects: 6
Study 8053577 — intervention group
Group type: COMPARATOR
Intervention: Leg-skin temperature near 32 degrees C
Number of subjects: 6
Study 8053577 — intervention group
Group type: COMPARATOR
Intervention: Leg-skin temperature near 36 degrees C
Number of subjects: 6
Study 8053577 — intervention group
Group type: COMPARATOR
Intervention: Leg-skin temperature near 38 degrees C
Number of subjects: 6
Study 2837304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal fibre
Number of subjects: 24
Study 2837304 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 24
Study 2837304 — intervention group
Group type: COMPARATOR
Intervention: Low fibre control diet
Number of subjects: 24
Study 30608051 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin MDA
Number of subjects: 0
Study 30608051 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 29182708 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin therapy (daily multivitamin with 5.0 mg folate, 1.0 mg vitamin B12, 50 mg vitamin B6)
Number of subjects: 584
Study 29182708 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily multi-vitamin with no folate, 2.0 µg vitamin B12, 1.4 mg vitamin B6)
Number of subjects: 584
Study 25003777 — intervention group
Group type: EXPERIMENTAL
Intervention: Meetup™
Number of subjects: 102
Study 25003777 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association condition
Number of subjects: 102
Study 23615159 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with low-dose ASA (100 mg)
Number of subjects: 126
Study 23615159 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with high-dose ASA (325 mg)
Number of subjects: 126
Study 23615159 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg coadministered with naproxen (500 mg)
Number of subjects: 126
Study 23615159 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban alone
Number of subjects: 126
Study 21544078 — intervention group
Group type: EXPERIMENTAL
Intervention: NPO‐11 (L-menthol preparation)
Number of subjects: 0
Study 19176561 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 2673
Study 19176561 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment (control)
Number of subjects: 2673
Study 17917526 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg every other day)
Number of subjects: 39876
Study 17917526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 15153053 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) interventions
Number of subjects: 0
Study 15153053 — intervention group
Group type: COMPARATOR
Intervention: Reminder/recall
Number of subjects: 0
Study 12556095 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% for three months and then as required
Number of subjects: 137
Study 12556095 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% for six months on a regular basis
Number of subjects: 137
Study 10080200 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle‐supported anterior chamber intraocular lenses (PIOLs)
Number of subjects: 263
Study 8526176 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 micrograms/24 hours
Number of subjects: 33
Study 8526176 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone (BDP) 800 micrograms/24 hours
Number of subjects: 33
Study 8526176 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (BUD and BDP)
Number of subjects: 33
Study 10147632 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional immunosuppression plus local graft irradiation (150 rads on days 1, 3, and 5)
Number of subjects: 100
Study 10147632 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression alone
Number of subjects: 100
Study 6107099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temazepam 20 mg
Number of subjects: 2
Study 6107099 — intervention group
Group type: COMPARATOR
Intervention: i.v. diazepam (titrated doses)
Number of subjects: 2
Study 6107099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral temazepam and i.v. diazepam
Number of subjects: 2
Study 6107099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temazepam
Number of subjects: 2
Study 31039261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program, sessions of 90 to 95 minutes, twice per week for 12 weeks
Number of subjects: 0
Study 31039261 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program
Number of subjects: 0
Study 31039261 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29021115 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded-BHC arm
Number of subjects: 333
Study 29021115 — intervention group
Group type: COMPARATOR
Intervention: Pediatrician-only arm
Number of subjects: 333
Study 29021115 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 333
Study 27140797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasiglifam 50 mg
Number of subjects: 280
Study 27140797 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasiglifam 400 mg
Number of subjects: 280
Study 27140797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 27140797 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 280
Study 23497264 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone based intervention promoting positive lifestyle modifications
Number of subjects: 0
Study 23497264 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 21380493 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer network-based intervention in intervention beer halls
Number of subjects: 413
Study 21380493 — intervention group
Group type: COMPARATOR
Intervention: Control group in control beer halls
Number of subjects: 413
Study 19412939 — intervention group
Group type: EXPERIMENTAL
Intervention: Early untreated PD subjects with clinically significant depressive symptoms (GDS-15 score > or = 5)
Number of subjects: 413
Study 19412939 — intervention group
Group type: EXPERIMENTAL
Intervention: Early untreated PD subjects
Number of subjects: 413
Study 19412939 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with mild depressive symptoms
Number of subjects: 413
Study 19412939 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing severity of depressive symptoms, older age, and longer PD duration
Number of subjects: 413
Study 17400684 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous treprostinil
Number of subjects: 22
Study 17400684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15460380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment protocol
Number of subjects: 124
Study 15460380 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 11349751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention program
Number of subjects: 0
Study 9310221 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interferon-beta la (r-hIFN-beta-1a)
Number of subjects: 124
Study 9310221 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 124
Study 8103982 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg IV every 6 hours)
Number of subjects: 118
Study 8103982 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 118
Study 3746900 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic Phrases
Number of subjects: 136
Study 3746900 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) Biofeedback
Number of subjects: 136
Study 3746900 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Biofeedback
Number of subjects: 136
Study 3746900 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 136
Study 31090592 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic peripheral blood serum (allo‐PBS) eye drops 8 times a day for 30 days
Number of subjects: 30
Study 31090592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood serum (CBS) eye drops 8 times a day for 30 days
Number of subjects: 30
Study 31090592 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (allo‐PBS and CBS)
Number of subjects: 30
Study 28730743 — intervention group
Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 125
Study 28730743 — intervention group
Group type: COMPARATOR
Intervention: Inulin-type fructans (ITF)
Number of subjects: 125
Study 28730743 — intervention group
Group type: COMPARATOR
Intervention: ITF + Whey protein
Number of subjects: 125
Study 28730743 — intervention group
Group type: COMPARATOR
Intervention: ITF
Number of subjects: 125
Study 28730743 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 125
Study 26465290 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid protocol (10ml/kg/hr)
Number of subjects: 66
Study 26465290 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid protocol (5ml/kg/hr)
Number of subjects: 66
Study 23354282 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 30
Study 23354282 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 20658564 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg daily
Number of subjects: 0
Study 20658564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19815891 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day doxycycline (200 mg/day) followed by single-dose diethylcarbamazine
Number of subjects: 57
Study 19815891 — intervention group
Group type: COMPARATOR
Intervention: 10-day doxycycline (200 mg/day) followed by single-dose diethylcarbamazine
Number of subjects: 57
Study 19815891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 19815891 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day doxycycline (200 mg/day)
Number of subjects: 57
Study 19815891 — intervention group
Group type: COMPARATOR
Intervention: 10-day doxycycline (200 mg/day)
Number of subjects: 57
Study 17713336 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 ppm F/pH 5.5 dentifrice
Number of subjects: 19
Study 17713336 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 ppm F/NaF/silica, pH 5.5
Number of subjects: 19
Study 17713336 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,100 ppm F/NaF/silica, pH 7.0
Number of subjects: 19
Study 17713336 — intervention group
Group type: COMPARATOR
Intervention: 1,100 ppm F/NaF/silica, pH 6.5 (gold standard)
Number of subjects: 19
Study 17713336 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 ppm F/MFP/CaCO3, pH 9.5
Number of subjects: 19
Study 15121364 — intervention group
Group type: EXPERIMENTAL
Intervention: Total anterior capsule cover (360 degrees) of the optic
Number of subjects: 202
Study 15121364 — intervention group
Group type: EXPERIMENTAL
Intervention: No anterior capsule cover (360 degrees) of the optic
Number of subjects: 202
Study 15121364 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial anterior capsule cover (<360 degrees) of the optic
Number of subjects: 202
Study 11287037 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP11a (tttta)(n) repeat‐polymorphism genotype
Number of subjects: 125
Study 11287037 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of the four‐repeat‐units allele (4R‐‐ genotype)
Number of subjects: 125
Study 11287037 — intervention group
Group type: COMPARATOR
Intervention: Serum hormone concentrations in 4R‐‐ individuals
Number of subjects: 125
Study 9444504 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual mannequins (Actar 911 and Laerdal Little Anne)
Number of subjects: 165
Study 9444504 — intervention group
Group type: COMPARATOR
Intervention: Control group (sophisticated mannequin - Laerdal Recording Resusci Anne)
Number of subjects: 165
Study 12959309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (1, 2, 4 microg kg(‐1))
Number of subjects: 15
Study 12959309 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (2.5, 5, 10 microg kg(‐1))
Number of subjects: 15
Study 12959309 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (2 microg kg(‐1))
Number of subjects: 15
Study 12959309 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 microg kg(‐1))
Number of subjects: 15
Study 3427209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg (fed)
Number of subjects: 12
Study 3427209 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil 500 mg (fasted)
Number of subjects: 12
Study 3427209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (fed)
Number of subjects: 12
Study 3427209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (various doses)
Number of subjects: 12
Study 2203940 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (including PCVm and ACVD regimens)
Number of subjects: 340
Study 2203940 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of PCVm (cisplatinum, cyclophosphamide, Vm 26) to ACVD (adriamycine, cyclophosphamide, vincristine, dacarbazine) in trial NB 82
Number of subjects: 340
Study 2203940 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (NB 82)
Number of subjects: 340
Study 2203940 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter intervals for realization of chemotherapy (NB 85)
Number of subjects: 340
Study 2203940 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 340
Study 165029 — intervention group
Group type: EXPERIMENTAL
Intervention: tibric acid 1,000 mg
Number of subjects: 50
Study 165029 — intervention group
Group type: EXPERIMENTAL
Intervention: tibric acid 1,250 mg
Number of subjects: 50
Study 165029 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 165029 — intervention group
Group type: EXPERIMENTAL
Intervention: tibric acid 500 mg
Number of subjects: 50
Study 165029 — intervention group
Group type: EXPERIMENTAL
Intervention: tibric acid 750 mg
Number of subjects: 50
Study 165029 — intervention group
Group type: EXPERIMENTAL
Intervention: tibric acid (all doses)
Number of subjects: 50
Study 31612281 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Er:YAG laser therapy
Number of subjects: 33
Study 28723333 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced antimicrobial prophylaxis (continuous trimethoprim-sulfamethoxazole, at least 12 weeks of isoniazid-pyridoxine, 12 weeks of fluconazole, 5 days of azithromycin, single dose of albendazole)
Number of subjects: 1805
Study 28723333 — intervention group
Group type: COMPARATOR
Intervention: Standard prophylaxis (trimethoprim-sulfamethoxazole alone)
Number of subjects: 1805
Study 25283502 — intervention group
Group type: EXPERIMENTAL
Intervention: TiN coated TKP
Number of subjects: 101
Study 25283502 — intervention group
Group type: COMPARATOR
Intervention: Uncoated TKP
Number of subjects: 101